Tecentriq Now FDA Approved for Treatment of Alveolar Soft-Part Sarcoma.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 22
- Publication type:
- Article
Works matching IS 21644403 AND DT 2023 AND VI 13 AND IP 3
Results: 19
1
2
Brukinsa Now FDA Approved for Patients with CLL or SLL.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 22
- Publication type:
- Article
3
Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive, Unresectable or Metastatic Colorectal Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 21
- Publication type:
- Article
4
Keytruda Receives FDA Approval for Adjuvant Treatment of NSCLC.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 21
- Publication type:
- Article
5
Trodelvy Now Approved for Pretreated Patients with HRPositive, HER2-Negative Breast Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 20
- Publication type:
- Article
6
Krazati Receives Accelerated FDA Approval for NSCLC with KRAS<sup>G12C</sup> Mutation.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 20
- Publication type:
- Article
7
Adstiladrin, First Adenoviral Vector-Based Gene Therapy, FDA Approved for High-Risk Non-Muscle-Invasive Bladder Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 20
- Publication type:
- Article
8
FDA Grants Lunsumio Accelerated Approval for Relapsed or Refractory Follicular Lymphoma.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 18
- Publication type:
- Article
9
Jaypirca Receives FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 18
- Publication type:
- Article
10
Orserdu FDA Approved for ER-Positive, Advanced or Metastatic Breast Cancer with ESR1 Mutation.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 18
- Publication type:
- Article
11
The End of the COVID-19 Public Health Emergency: What Are the Implications for Your Practice?
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 16
- By:
- Publication type:
- Article
12
RIT Researcher Develops Math Models to Help Predict Patients' Medication Adherence.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 15
- By:
- Publication type:
- Article
13
Young Women with Breast Cancer May Safely Pause Endocrine Therapy to Pursue Pregnancy.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 14
- By:
- Publication type:
- Article
14
Increased Use of Telehealth Could Reduce Financial Burden of Oncology Services for Some Patients.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 12
- Publication type:
- Article
15
IQVIA Predicts US Spending on Biosimilars Will Reach $129 Billion by 2027.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 11
- Publication type:
- Article
16
Choosing Adjuvant Therapies in Patients with RCC Requires Careful Consideration of Risks and Benefits.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 7
- By:
- Publication type:
- Article
17
Researchers 3D Bioprint Breast Cancer Tumors, Treat Them in Groundbreaking Study.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 1
- Publication type:
- Article
18
Study Finds Disparities in Access to Opioids for Cancer Pain at End of Life.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 1
- Publication type:
- Article
19
Darolutamide Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 3, p. 1
- By:
- Publication type:
- Article